Shasun Pharmaceuticals has surged 8% to Rs 77.70 after the company said it has successfully completed United States' Food and Drugs Administration (USFDA) and Brazilian ANVISA (National Health Surveillance Agency) inspections of API facility at Puducherry.
“The regulatory authorities have concluded that the facility, systems and practices comply with their requirements and there were no recommendations or observations,” Shasun Pharma said in a press release.
The stock opened at Rs 72.60 and touched high of Rs 79.50 on BSE. A combined 1.36 million shares have changed hands on the counter till early noon deals against an average around 1 million shares that were traded daily in past two weeks on BSE and NSE.
“The regulatory authorities have concluded that the facility, systems and practices comply with their requirements and there were no recommendations or observations,” Shasun Pharma said in a press release.
The stock opened at Rs 72.60 and touched high of Rs 79.50 on BSE. A combined 1.36 million shares have changed hands on the counter till early noon deals against an average around 1 million shares that were traded daily in past two weeks on BSE and NSE.
